Progress in clinical fibrinolysis

[1] ACHBAROU A, 1994, CANCER RES, V54, P2372

[2] ANDERSON GI, 1995, J BONE MINER RES S1, V10, pS284

[3] BACHMAN F, 1995, FIBRINOLYSIS DIS, V1, P79

[4] TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) : 16603 - 16608

[5] BASHKOV GV, 1993, BLOOD COAGUL FIBRIN, V4, P993

[6] BAVENHOLM P, 1995, THROMB HAEMOSTASIS, V73, P568

[7] BEER JH, 1994, THROMB HAEMOSTASIS, V71, P622

[8] NEW VARIANT OF HUMAN TISSUE-PLASMINOGEN ACTIVATOR (TPA) WITH ENHANCED EFFICACY AND LOWER INCIDENCE OF BLEEDING COMPARED WITH RECOMBINANT HUMAN TPA [J]. CIRCULATION, 1995, 92 (10) : 3032 - 3040

[9] ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE PATHOGENESIS AND OUTCOME OF THE HEMOLYTIC UREMIC SYNDROME [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) : 755 - 759

[10] BIANCHI E, 1994, CANCER RES, V54, P861

[1] ACHBAROU A, 1994, CANCER RES, V54, P2372

[2] ANDERSON GI, 1995, J BONE MINER RES S1, V10, pS284

[3] BACHMAN F, 1995, FIBRINOLYSIS DIS, V1, P79

[4] TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) : 16603 - 16608

[5] BASHKOV GV, 1993, BLOOD COAGUL FIBRIN, V4, P993

[6] BAVENHOLM P, 1995, THROMB HAEMOSTASIS, V73, P568

[7] BEER JH, 1994, THROMB HAEMOSTASIS, V71, P622

[8] NEW VARIANT OF HUMAN TISSUE-PLASMINOGEN ACTIVATOR (TPA) WITH ENHANCED EFFICACY AND LOWER INCIDENCE OF BLEEDING COMPARED WITH RECOMBINANT HUMAN TPA [J]. CIRCULATION, 1995, 92 (10) : 3032 - 3040

[9] ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE PATHOGENESIS AND OUTCOME OF THE HEMOLYTIC UREMIC SYNDROME [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) : 755 - 759

[10] BIANCHI E, 1994, CANCER RES, V54, P861